- Report
- October 2024
- 190 Pages
Global
From €3383EUR$3,545USD£2,835GBP
€3759EUR$3,939USD£3,150GBP
- Report
- November 2024
- 69 Pages
Global
From €3813EUR$3,995USD£3,195GBP
- Report
- May 2024
- 129 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Drug Pipelines
- April 2024
- 220 Pages
Global
From €2863EUR$3,000USD£2,399GBP
- Report
- July 2023
- 220 Pages
Global
From €1899EUR$1,990USD£1,591GBP
- Report
- January 2022
- 200 Pages
Global
From €7158EUR$7,500USD£5,997GBP
- Report
- January 2022
- 60 Pages
Global
From €3770EUR$3,950USD£3,159GBP
- Report
- February 2024
- 180 Pages
Global
From €4742EUR$4,969USD£3,973GBP
- Report
- August 2021
Global
From €3808EUR$3,990USD£3,191GBP
- Report
- October 2022
- 548 Pages
Global
From €2386EUR$2,500USD£1,999GBP
The Type 1 Diabetes Drug market is a subset of the Immune Disorders Drugs market. It is composed of drugs used to treat Type 1 Diabetes, an autoimmune disorder in which the body's immune system attacks the cells that produce insulin. These drugs are used to help regulate blood sugar levels and reduce the risk of complications associated with the disease. Commonly used Type 1 Diabetes Drugs include insulin, sulfonylureas, meglitinides, and GLP-1 agonists. These drugs are typically administered orally or through injection.
The Type 1 Diabetes Drug market is highly competitive, with many companies offering a variety of products. Some of the major players in the market include Novo Nordisk, Sanofi, Eli Lilly, Merck, and Boehringer Ingelheim. Show Less Read more
